Pharmacies are essential services and will remain open, but some people will still have problems accessing medicines. Here’s what you can do.
Articles on Pharmaceuticals
Displaying 121 - 140 of 262 articles
There are plenty of ways to keep your mind and body active and healthy during the outbreak.
Inspired by amber and hard candy, researchers figured out a new, needle-free, shelf-stable way to preserve vaccines, making them easier to ship and administer around the world.
PODCAST: The third part of a series from The Anthill podcast on how personalised medicine may become in the future.
While US residents may feel safe from the effects of the coronavirus, the aftershocks could be damaging in unexpected ways. The disruption to China’s supply chain could cause drug shortages.
Sedatives contributed to a pharmaceutical revolution in South Africa in the divided 1950s, especially among white users.
There are two histories of dagga in South Africa - the one of criminalising it and the other of the state trying to make money off it.
Opium played a fascinating role in southern African colonial politics, conflict and social change - from the poppy fields of Mozambique to the early days of Johannesburg city.
From colonial poppy fields to pharmatrash, southern Africa offers a fascinating history of drug regimes – one that helps us make sense of drug policies and legislation today.
Too often, pharmaceutical companies and device manufacturers exert influence in how their products are tested in the research phase and recommended in the clinic.
Prominent GP and former MP Kerryn Phelps has weighed into the doctor-pharmacist turf war, saying pharmacists shouldn’t prescribe because of their financial interests. But the evidence says otherwise.
During bushfire season, managing medication as well as respiratory conditions should be part of any emergency plan.
For most medicines, it doesn’t matter when you take them. But others work best at particular times.
There’s a big market for new treatments for TB, malaria and other ailments. But most of these diseases afflict low-income people unable to pay for medicine.
While critics accuse companies facing lots of lawsuits of using bankruptcy as a sort of ‘get of jail free card,’ the reality of the legal procedure is more complicated.
Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
The first study to assess the carbon footprint of the pharmaceutical industry finds that it is far from green.
American companies still face enormous uncertainty about how they’ll be doing business in the UK and EU in the coming years, particularly as the April 12 Brexit deadline draws closer.
A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
Top contributors
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Director and Taylor Family Chair, Centre for the Business & Economics of Health, The University of Queensland
-
Lecturer Pharmacy Practice, University of Sydney
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Pharmacist and PhD Candidate, University of Sydney
-
Professor of Bioethics, Macquarie University
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor of Trade Law and Taxation, Queensland University of Technology
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
PhD Candidate, Swinburne University of Technology
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Senior Lecturer, Pharmacy, Aston University
-
Professor of Economics, Loughborough University